Institute of Human Genetics, Ulm University and Ulm University Medical Center, Ulm, 89081, Germany; Institute of Human Genetics, Christian-Albrechts-University, Kiel, 24105.
Max-Delbruck-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, 13125, Germany; Hematology, Oncology and Tumor Immunology, Charite - Universitatsmedizin Berlin, Berlin, 12200, Germany, and Experimental and Clinical Research Center, a joint cooperation between the MDC and the Charite, Berlin, 13125.
Haematologica. 2023 Feb 1;108(2):543-554. doi: 10.3324/haematol.2021.280005.
Histone methylation-modifiers, such as EZH2 and KMT2D, are recurrently altered in B-cell lymphomas. To comprehensively describe the landscape of alterations affecting genes encoding histone methylation-modifiers in lymphomagenesis we investigated whole genome and transcriptome data of 186 mature B-cell lymphomas sequenced in the ICGC MMML-Seq project. Besides confirming common alterations of KMT2D (47% of cases), EZH2 (17%), SETD1B (5%), PRDM9 (4%), KMT2C (4%), and SETD2 (4%), also identified by prior exome or RNA-sequencing studies, we here found recurrent alterations to KDM4C in chromosome 9p24, encoding a histone demethylase. Focal structural variation was the main mechanism of KDM4C alterations, and was independent from 9p24 amplification. We also identified KDM4C alterations in lymphoma cell lines including a focal homozygous deletion in a classical Hodgkin lymphoma cell line. By integrating RNA-sequencing and genome sequencing data we predict that KDM4C structural variants result in loss-offunction. By functional reconstitution studies in cell lines, we provide evidence that KDM4C can act as a tumor suppressor. Thus, we show that identification of structural variants in whole genome sequencing data adds to the comprehensive description of the mutational landscape of lymphomas and, moreover, establish KDM4C as a putative tumor suppressive gene recurrently altered in subsets of B-cell derived lymphomas.
组蛋白甲基化修饰因子,如 EZH2 和 KMT2D,在 B 细胞淋巴瘤中经常发生改变。为了全面描述影响组蛋白甲基化修饰因子的基因改变在淋巴瘤发生中的图谱,我们研究了 186 例成熟 B 细胞淋巴瘤的全基因组和转录组数据,这些淋巴瘤是在 ICGC MMML-Seq 项目中测序的。除了确认先前外显子组或 RNA-seq 研究中发现的 KMT2D(47%的病例)、EZH2(17%)、SETD1B(5%)、PRDM9(4%)、KMT2C(4%)和 SETD2(4%)的常见改变外,我们还发现了 9p24 上编码组蛋白去甲基化酶的 KDM4C 的反复改变。染色体 9p24 的局部结构变异是 KDM4C 改变的主要机制,与 9p24 扩增无关。我们还在淋巴瘤细胞系中发现了 KDM4C 的改变,包括在经典霍奇金淋巴瘤细胞系中存在局部纯合缺失。通过整合 RNA-seq 和基因组测序数据,我们预测 KDM4C 的结构变异导致功能丧失。通过在细胞系中的功能重建研究,我们提供了证据表明 KDM4C 可以作为肿瘤抑制因子。因此,我们表明,在全基因组测序数据中识别结构变体增加了对淋巴瘤突变景观的全面描述,并且,此外,确立了 KDM4C 作为在 B 细胞衍生的淋巴瘤亚群中经常改变的潜在肿瘤抑制基因。